In 2018, Grindeks will strategically focus on complex solutions to meet the needs of patients. The turnover growth this year will be reached by raising export volume to the EU countries, Russia and other CIS countries, the U.S., Canada, Japan and Vietnam, and, also, entering new markets. The strategic markets for business development in 2018 will be the European Union and Southeast Asia countries.
In addition to entering new markets Grindeks also is planning to make significant investments in development. Kirovs Lipmans, the Chairman of the Council of JSC Grindeks, remarked: “The major factor to boost production is increase in demand. This raises the issue of necessary production capacity; therefore, this year we will invest at least 7 million euro in our manufacturing facilities in Latvia, Estonia and Slovakia.”
Detailed information on Grindeks results of the last year will be submitted to “Nasdaq Riga” on 28 February 2018 when non-audited interim financial statement for the 12-month period of 2017 will be published in accordance with the financial calendar of this year.